Vogelstein, B. & Kinzler, K. W. The multistep nature of cancer. Trends Genet.9, 138–141 (1993). ArticleCASPubMed Google Scholar
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunol.3, 991–998 (2002). This is an insightful review on the mechanisms of immune surveillance and immune editing of tumours. ArticleCAS Google Scholar
Pardoll, D. Does the immune system see tumors as foreign or self? Annu. Rev. Immunol.21, 807–839 (2003). ArticleCASPubMed Google Scholar
Blattman, J. N. & Greenberg, P. D. Cancer immunotherapy: a treatment for the masses. Science305, 200–205 (2004). ArticleCASPubMed Google Scholar
Gabrilovich, D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nature Rev. Immunol.4, 941–952 (2004). ArticleCAS Google Scholar
Zou, W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nature Rev. Cancer5, 263–274 (2005). ArticleCAS Google Scholar
Bissell, M. J. & Radisky, D. Putting tumours in context. Nature Rev. Cancer1, 46–54 (2001). ArticleCAS Google Scholar
Pollard, J. W. Tumour-educated macrophages promote tumour progression and metastasis. Nature Rev. Cancer4, 71–78 (2004). ArticleCAS Google Scholar
Yu, C. L. et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science269, 81–83 (1995). This study provides the first evidence that STAT3 has a role in oncogenesis in that STAT3 is constitutively activated by SRC oncoprotein. ArticleCASPubMed Google Scholar
Bromberg, J. & Darnell, J. E. The role of STATs in transcriptional control and their impact on cellular function. Oncogene19, 2468–2473 (2000). ArticleCASPubMed Google Scholar
Yu, H. & Jove, R. The STATs of cancer — new molecular targets come of age. Nature Rev. Cancer4, 97–105 (2004). A comprehensive review on the role of STAT3 in cancer progression and on STAT3 as a target for cancer therapy. ArticleCAS Google Scholar
Takeda, K. et al. Enhanced TH1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity10, 39–49 (1999). ArticleCASPubMed Google Scholar
Welte, T. et al. STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity. Proc. Natl Acad. Sci. USA100, 1879–1884 (2003). ArticleCASPubMedPubMed Central Google Scholar
Wang, T. et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nature Med.10, 48–54 (2004). This study provided the first evidence at the molecular level that oncogenesis, for which STAT3 is crucial, coordinates tumour immune evasion. STAT3 activity in tumour cells not only inhibits the expression of TH1-type immune-stimulating molecules, it also promotes the expression of immunosuppressive factors, leading to the inhibition of DC maturation. ArticlePubMedCAS Google Scholar
Kortylewski, M. et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nature Med.11, 1314–1321 (2005). This study shows that STAT3 is constitutively activated in diverse immune-cell subsets in the tumour microenvironment. STAT3 signalling allows tumour cells and local immune cells to resonate with one another, leading to immunosuppression. ArticleCASPubMed Google Scholar
Nabarro, S. et al. Coordinated oncogenic transformation and inhibition of host immune responses by the PAX3–FKHR fusion oncoprotein. J. Exp. Med.202, 1399–1410 (2005). This paper shows that activation of STAT3 by an oncoprotein inhibits the host immune response in mouse models. ArticleCASPubMedPubMed Central Google Scholar
Sumimoto, H., Imabayashi, F., Iwata, T. & Kawakami, Y. The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J. Exp. Med.203, 1651–1656 (2006). Results from this paper show that both STAT3 activation and the BRAF–MAPK signalling pathway can promote the expression of immunosuppressive factors such as IL-6, IL-10 and VEGF in human melanoma cells. Blocking either of these oncogenic signalling pathways in DCs decreases tumour-factor-induced inhibition of IL-12 expression. ArticleCASPubMedPubMed Central Google Scholar
Darnell, J. E., Kerr, I. M. & Stark, G. R. Jak–STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science264, 1415–1421 (1994). ArticleCASPubMed Google Scholar
Taga, T. & Kishimoto, T. Gp130 and the interleukin-6 family of cytokines. Annu. Rev. Immunol.15, 797–819 (1997). ArticleCASPubMed Google Scholar
Heinrich, P. C., Behrmann, I., Muller-Newen, G., Schaper, F. & Graeve, L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J.334, 297–314 (1998). ArticleCASPubMedPubMed Central Google Scholar
Darnell, J. E. Studies of IFN-induced transcriptional activation uncover the Jak–Stat pathway. J. Interferon Cytokine Res.18, 549–554 (1998). ArticleCASPubMed Google Scholar
Stark, G. R., Kerr, I. M., Williams, B. R., Silverman, R. H. & Schreiber, R. D. How cells respond to interferons. Annu. Rev. Biochem.67, 227–264 (1998). ArticleCASPubMed Google Scholar
Wang, R., Cherukuri, P. & Luo, J. Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation. J. Biol. Chem.280, 11528–11534 (2005). ArticleCASPubMed Google Scholar
Yuan, Z. L., Guan, Y. J., Chatterjee, D. & Chin, Y. E. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science307, 269–273 (2005). ArticleCASPubMed Google Scholar
Silvennoinen, O., Schindler, C., Schlessinger, J. & Levy, D. E. Ras-independent growth factor signaling by transcription factor tyrosine phosphorylation. Science261, 1736–1739 (1993). ArticleCASPubMed Google Scholar
Zhong, Z., Wen, Z. & Darnell, J. E. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science264, 95–98 (1994). ArticleCASPubMed Google Scholar
Ruff-Jamison, S. et al. Epidermal growth factor and lipopolysaccharide activate Stat3 transcription factor in mouse liver. J. Biol. Chem.269, 21933–21935 (1994). ArticleCASPubMed Google Scholar
Alexander, W. S. Suppressors of cytokine signalling (SOCS) in the immune system. Nature Rev. Immunol.2, 410–416 (2002). ArticleCAS Google Scholar
Kubo, M., Hanada, T. & Yoshimura, A. Suppressors of cytokine signaling and immunity. Nature Immunol.4, 1169–1176 (2003). ArticleCAS Google Scholar
Shuai, K. & Liu, B. Regulation of gene-activation pathways by PIAS proteins in the immune system. Nature Rev. Immunol.5, 593–605 (2005). ArticleCAS Google Scholar
Turkson, J. et al. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol. Cell. Biol.18, 2545–2552 (1998). ArticleCASPubMedPubMed Central Google Scholar
Bromberg, J. F., Horvath, C. M., Besser, D., Lathem, W. W. & Darnell, J. E. Stat3 activation is required for cellular transformation by v-src. Mol. Cell. Biol.18, 2553–2558 (1998). ArticleCASPubMedPubMed Central Google Scholar
Bromberg, J. F. et al. Stat3 as an oncogene. Cell98, 295–303 (1999). Using a constitutively active mutant form of STAT3, this study formally establishes that STAT3 is an oncoprotein. ArticleCASPubMed Google Scholar
Catlett-Falcone, R. et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity10, 105–115 (1999). ArticleCASPubMed Google Scholar
Grandis, J. R. et al. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J. Clin. Invest.102, 1385–1392 (1998). ArticleCASPubMedPubMed Central Google Scholar
Coffer, P. J., Koenderman, L. & de Groot, R. P. The role of STATs in myeloid differentiation and leukemia. Oncogene19, 2511–2522 (2000). ArticleCASPubMed Google Scholar
Lin, T. S., Mahajan, S. & Frank, D. A. STAT signaling in the pathogenesis and treatment of leukemias. Oncogene19, 2496–2504 (2000). ArticleCASPubMed Google Scholar
Kortylewski, M., Jove, R. & Yu, H. Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev.24, 315–327 (2005). ArticleCASPubMed Google Scholar
Niu, G. et al. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res.59, 5059–5063 (1999). CASPubMed Google Scholar
Niu, G. et al. Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res.61, 3276–3280 (2001). CASPubMed Google Scholar
Niu, G. et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene21, 2000–2008 (2002). ArticleCASPubMed Google Scholar
Wei, D. et al. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene22, 319–329 (2003). ArticleCASPubMed Google Scholar
Wei, L. H. et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene22, 1517–1527 (2003). ArticleCASPubMed Google Scholar
Xu, Q. et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene24, 5552–5560 (2005). ArticleCASPubMed Google Scholar
Wojcik, E. J. et al. A novel activating function of c-Src and Stat3 on HGF transcription in mammary carcinoma cells. Oncogene25, 2773–2784 (2006). ArticleCASPubMed Google Scholar
Xie, T. X. et al. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene23, 3550–3560 (2004). ArticleCASPubMed Google Scholar
Dechow, T. N. et al. Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc. Natl Acad. Sci. USA101, 10602–10607 (2004). ArticleCASPubMedPubMed Central Google Scholar
Burdelya, L. et al. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J. Immunol.174, 3925–3931 (2005). ArticleCASPubMed Google Scholar
Vicari, A. P., Caux, C. & Trinchieri, G. Tumour escape from immune surveillance through dendritic cell inactivation. Semin. Cancer Biol.12, 33–42 (2002). ArticleCASPubMed Google Scholar
Steinman, R. M., Hawiger, D. & Nussenzweig, M. C. Tolerogenic dendritic cells. Annu. Rev. Immunol.21, 685–711 (2003). ArticleCASPubMed Google Scholar
Nefedova, Y. et al. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J. Immunol.172, 464–474 (2004). ArticleCASPubMed Google Scholar
Park, S. J. et al. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J. Immunol.173, 3844–3854 (2004). ArticleCASPubMed Google Scholar
Kawakami, Y. et al. Regulation of dendritic cell maturation and function by Bruton's tyrosine kinase via IL-10 and Stat3. Proc. Natl Acad. Sci. USA103, 153–158 (2006). ArticleCASPubMed Google Scholar
Cheng, F. et al. A critical role for Stat3 signaling in immune tolerance. Immunity19, 425–436 (2003). ArticleCASPubMed Google Scholar
Sun, Z., Yao, Z., Liu, S., Tang, H. & Yan, X. An oligonucleotide decoy for Stat3 activates the immune response of macrophages to breast cancer. Immunobiology211, 199–209 (2006). ArticleCASPubMed Google Scholar
Yu, P. et al. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J. Exp. Med.201, 779–791 (2005). ArticleCASPubMedPubMed Central Google Scholar
Nishikawa, H. et al. IFN-γ controls the generation/activation of CD4+ CD25+ regulatory T cells in antitumor immune response. J. Immunol.175, 4433–4440 (2005). ArticleCASPubMed Google Scholar
Larmonier, N. et al. Tumor-derived CD4+CD25+ regulatory T cell suppression of dendritic cell function involves TGF-β and IL-10. Cancer Immunol. Immunother.56, 48–59 (2007). ArticleCASPubMed Google Scholar
Liyanage, U. K. et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol.169, 2756–2761 (2002). ArticleCASPubMed Google Scholar
Woo, E. Y. et al. Regulatory CD4+CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res.61, 4766–4772 (2001). CASPubMed Google Scholar
Zou, W. Regulatory T cells, tumour immunity and immunotherapy. Nature Rev. Immunol.6, 295–307 (2006). ArticleCAS Google Scholar
Curiel, T. J. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Med.10, 942–949 (2004). ArticleCASPubMed Google Scholar
Wei, S. et al. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res.65, 5020–5026 (2005). ArticleCASPubMed Google Scholar
Sakaguchi, S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nature Immunol.6, 345–352 (2005). ArticleCAS Google Scholar
Shevach, E. M. CD4+ CD25+ suppressor T cells: more questions than answers. Nature Rev. Immunol.2, 389–400 (2002). ArticleCAS Google Scholar
Chen, W. et al. Conversion of peripheral CD4+CD25− naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3. J. Exp. Med.198, 1875–1886 (2003). ArticleCASPubMedPubMed Central Google Scholar
Fantini, M. C. et al. Cutting edge: TGF-β induces a regulatory phenotype in CD4+CD25− T cells through Foxp3 induction and down-regulation of Smad7. J. Immunol.172, 5149–5153 (2004). ArticleCASPubMed Google Scholar
Kinjyo, I. et al. Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor-β1. J. Exp. Med.203, 1021–1031 (2006). This study shows that increased STAT3 signalling, as a result ofSocs3ablation, is crucial for the expression of IL-10 and TGF-β by THcells, indicating a crucial role for STAT3 in TRegcells. ArticleCASPubMedPubMed Central Google Scholar
Kasprzycka, M., Marzec, M., Liu, X., Zhang, Q. & Wasik, M. A. Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. Proc. Natl Acad. Sci. USA103, 9964–9969 (2006). ArticleCASPubMedPubMed Central Google Scholar
Doganci, A. et al. The IL-6Rα chain controls lung CD4+CD25+ TR eg development and function during allergic airway inflammation in vivo. J. Clin. Invest.115, 313–325 (2005). ArticleCASPubMedPubMed Central Google Scholar
Zorn, E. et al. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood108, 1571–1579 (2006). This paper shows that IL-2-induced FOXP3 expression in human TRegcells is mediated by STAT3 and STAT5. ArticleCASPubMedPubMed Central Google Scholar
Antov, A., Yang, L., Vig, M., Baltimore, D. & Van Parijs, L. Essential role for STAT5 signaling in CD25+CD4+ regulatory T cell homeostasis and the maintenance of self-tolerance. J. Immunol.171, 3435–3441 (2003). ArticleCASPubMed Google Scholar
Snow, J. W. et al. Loss of tolerance and autoimmunity affecting multiple organs in STAT5A/5B-deficient mice. J. Immunol.171, 5042–5050 (2003). ArticleCASPubMed Google Scholar
Chan, S. M., Ermann, J., Su, L., Fathman, C. G. & Utz, P. J. Protein microarrays for multiplex analysis of signal transduction pathways. Nature Med.10, 1390–1396 (2004). ArticleCASPubMed Google Scholar
Anderson, P. O. et al. IL-2 overcomes the unresponsiveness but fails to reverse the regulatory function of antigen-induced T regulatory cells. J. Immunol.174, 310–319 (2005). ArticleCASPubMed Google Scholar
Dercamp, C., Chemin, K., Caux, C., Trinchieri, G. & Vicari, A. P. Distinct and overlapping roles of interleukin-10 and CD25+ regulatory T cells in the inhibition of antitumor CD8 T-cell responses. Cancer Res.65, 8479–8486 (2005). ArticleCASPubMed Google Scholar
Langowski, J. L. et al. IL-23 promotes tumour incidence and growth. Nature442, 461–465 (2006). ArticleCASPubMed Google Scholar
Hoentjen, F., Sartor, R. B., Ozaki, M. & Jobin, C. STAT3 regulates NF-κB recruitment to the IL-12p40 promoter in dendritic cells. Blood105, 689–696 (2005). ArticleCASPubMed Google Scholar
Chen, Z. et al. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc. Natl Acad. Sci. USA103, 8137–8142 (2006). ArticleCASPubMedPubMed Central Google Scholar
Karin, M. & Greten, F. R. NF-κB: linking inflammation and immunity to cancer development and progression. Nature Rev. Immunol.5, 749–759 (2005). ArticleCAS Google Scholar
Dalwadi, H. et al. Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer. Clin. Cancer Res.11, 7674–7682 (2005). ArticleCASPubMed Google Scholar
Shankaran, V. et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature410, 1107–1111 (2001). ArticleCASPubMed Google Scholar
Alonzi, T. et al. Induced somatic inactivation of STAT3 in mice triggers the development of a fulminant form of enterocolitis. Cytokine26, 45–56 (2004). ArticleCASPubMed Google Scholar
Turkson, J. et al. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J. Biol. Chem.276, 45443–45455 (2001). ArticleCASPubMed Google Scholar
Turkson, J. et al. A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J. Biol. Chem.280, 32979–32988 (2005). ArticleCASPubMed Google Scholar
Turkson, J. et al. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol. Cancer Ther.3, 1533–1542 (2004). CASPubMed Google Scholar
van Elsas, A., Hurwitz, A. A. & Allison, J. P. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med.190, 355–366 (1999). ArticleCASPubMedPubMed Central Google Scholar
Riley, J. L. & June, C. H. The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. Blood105, 13–21 (2005). ArticleCASPubMed Google Scholar
Shen, L., Evel-Kabler, K., Strube, R. & Chen, S. Y. Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nature Biotechnol.22, 1546–1553 (2004). ArticleCAS Google Scholar
Kryczek, I. et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med.203, 871–881 (2006). ArticleCASPubMedPubMed Central Google Scholar
Mellor, A. L. & Munn, D. H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nature Rev. Immunol.4, 762–774 (2004). ArticleCAS Google Scholar
Rosenberg, S. A., Yang, J. C. & Restifo, N. P. Cancer immunotherapy: moving beyond current vaccines. Nature Med.10, 909–915 (2004). ArticleCASPubMed Google Scholar
Pardoll, D. M. Spinning molecular immunology into successful immunotherapy. Nature Rev. Immunol.2, 227–238 (2002). ArticleCAS Google Scholar
Steinman, R. M. & Mellman, I. Immunotherapy: bewitched, bothered, and bewildered no more. Science305, 197–200 (2004). ArticleCASPubMed Google Scholar
Vicari, A. P. et al. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J. Exp. Med.196, 541–549 (2002). ArticleCASPubMedPubMed Central Google Scholar
Nefedova, Y. et al. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res.65, 9525–9535 (2005). ArticleCASPubMedPubMed Central Google Scholar
Kitamura, H. et al. IL-6–STAT3 controls intracellular MHC class II αβ dimer level through cathepsin S activity in dendritic cells. Immunity23, 491–502 (2005). ArticleCASPubMed Google Scholar
Kammertoens, T., Schuler, T. & Blankenstein, T. Immunotherapy: target the stroma to hit the tumor. Trends Mol. Med.11, 225–231 (2005). ArticleCASPubMed Google Scholar
Wang, S. et al. Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. Blood107, 2432–2439 (2006). ArticleCASPubMedPubMed Central Google Scholar
Dauer, D. J. et al. Stat3 regulates genes common to both wound healing and cancer. Oncogene24, 3397–3408 (2005). ArticleCASPubMed Google Scholar
Sano, S. et al. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J.18, 4657–4668 (1999). ArticleCASPubMedPubMed Central Google Scholar
Chiarle, R. et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nature Med.11, 623–629 (2005). ArticleCASPubMed Google Scholar
Okada, S. et al. Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury. Nature Med.12, 829–834 (2006). ArticleCASPubMed Google Scholar
Odajima, J. et al. Full oncogenic activities of v-Src are mediated by multiple signaling pathways. Ras as an essential mediator for cell survival. J. Biol. Chem.275, 24096–24105 (2000). ArticleCASPubMed Google Scholar
Ning, Z. Q., Li, J., McGuinness, M. & Arceci, R. J. STAT3 activation is required for Asp816 mutant c-Kit induced tumorigenicity. Oncogene20, 4528–4536 (2001). ArticleCASPubMed Google Scholar
Bowman, T. et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc. Natl Acad. Sci. USA98, 7319–7324 (2001). ArticleCASPubMedPubMed Central Google Scholar
Sinibaldi, D. et al. Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. Oncogene19, 5419–5427 (2000). ArticleCASPubMed Google Scholar
Karni, R., Jove, R. & Levitzki, A. Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors. Oncogene18, 4654–4662 (1999). ArticleCASPubMed Google Scholar
Epling-Burnette, P. K. et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J. Clin. Invest.107, 351–362 (2001). ArticleCASPubMedPubMed Central Google Scholar
Niu, G. et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene21, 7001–7010 (2002). ArticleCASPubMed Google Scholar
Aoki, Y., Feldman, G. M. & Tosato, G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood101, 1535–1542 (2003). ArticleCASPubMed Google Scholar
Amin, H. M. et al. Selective inhibition of STAT3 induces apoptosis and G1 cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene23, 5426–5434 (2004). ArticleCASPubMed Google Scholar
Gritsko, T. et al. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin. Cancer Res.12, 11–19 (2006). ArticleCASPubMed Google Scholar
Hung, W. & Elliott, B. Co-operative effect of c-Src tyrosine kinase and Stat3 in activation of hepatocyte growth factor expression in mammary carcinoma cells. J. Biol. Chem.276, 12395–12403 (2001). ArticleCASPubMed Google Scholar
Xie, T. X. et al. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res.66, 3188–3196 (2006). ArticleCASPubMed Google Scholar
Jung, J. E. et al. STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells. FASEB J.19, 1296–1298 (2005). ArticleCASPubMed Google Scholar
Herbeuval, J. P., Lelievre, E., Lambert, C., Dy, M. & Genin, C. Recruitment of STAT3 for production of IL-10 by colon carcinoma cells induced by macrophage-derived IL-6. J. Immunol.172, 4630–4636 (2004). ArticleCASPubMed Google Scholar